The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the…

By N. Chalasani, Z. Younossi, J. Lavine, A. Diehl, E. Brunt, K. Cusi, M. Charlton, A. Sanyal. American Journal of Gastroenterology, 2012

2,216 citations recorded by the source corpus.

Subfields: Epidemiology, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/0867949b5fbdad62303e734294cf533eb8ad3141

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. Megan H. Bair-Merritt
4. K. Cusi
5. A. Sanyal
6. Gerald I. Shulman
7. R. Loomba
8. E. Brunt

In Pathology and Forensic Medicine

1. Z. Younossi
2. Q. Anstee
3. Shira Zelber-Sagi
4. A. Sanyal
5. M. Rinella
6. K. Cusi
7. E. Brunt
8. R. Loomba

In Surgery

1. Megan H. Bair-Merritt
2. Gerald I. Shulman
3. Bart Staels

Citations in the corpus

• Systematic reviews and meta-analyses (2009, background): “12 However, there are several pharmacologic treatments currently in development that speci fi cally target NASH and NAFLD.”
• Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus (2016, neutral): “Mean age (SD), y 49 (11) 52 (10) Male, n (%) 35 (69) 36 (72) T2DM, n (%) 28 (55) 24 (48) Ethnicity, n (%) White 11 (22) 14 (28) Hispanic 37 (73) 31 (62) Other 3 (6) 5 (10) Mean weight (SD), kg 99.”
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes (2016, background): “The high prevalence of MetS and hyperlipidemia in NAFLD patients suggests that risk stratification and aggressive treatment is needed to control the risk of CVD in these patients (for reference 129, please see the Supporting information).((1)) Long-term clinical outcomes of NAFLD were also assessed ”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, neutral): “Patients with NASH cirrhosis should be considered for HCC screening according to the American Association for the Study of Liver Diseases (AASLD)/American College of Gastroenterology (ACG) practice guidelines [175].”
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016, background): “NASH defines a subgroup of nonalcoholic fatty liver disease where liver steatosis coexists with hepatic cell injury (apoptosis and hepatocyte ballooning), and inflammation.(1) It occurs in close association with overweight/ obesity, type 2 diabetes, and cardiometabolic conditions that define the met”
• Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. (2014, background): “S.(5-7) The incidence of HCC among patients with NASH is not clearly defined.”
• Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 (2015, background): “Conclusions: NAFLD is becoming a major cause of HCC in the United States.”
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, background): “NAFLD ranges from isolated hepatic steatosis (non-alcoholic fatty liver; NAFL) to non-alcoholic steatohepatitis (NASH), the latter characterized by presence of lobular inflammation and hepatocyte ballooning, with or without fibrosis [5].”